# Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer

> **NCT05894694** · PHASE4 · RECRUITING · sponsor: **Guang'anmen Hospital of China Academy of Chinese Medical Sciences** · enrollment: 320 (estimated)

## Conditions studied

- Advanced Colorectal Carcinoma

## Interventions

- **DRUG:** first-line scheme+compound kushen injection
- **DRUG:** palliative care group first-line scheme

## Key facts

- **NCT ID:** NCT05894694
- **Lead sponsor:** Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-27
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05894694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05894694, "Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05894694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*